<?xml version="1.0" encoding="UTF-8"?>
<p>131-2G is a murine mAb that binds to the central conserved region of the RSV G protein and interferes with the attachment process by blocking the G protein from binding to CX3CR1 (
 <xref rid="ref73" ref-type="bibr">Johnson et al., 2015</xref>). RSV-challenged mice studies showed that early treatment with this mAb reduced both pulmonary inflammation and lung virus titers (
 <xref rid="ref64" ref-type="bibr">Haynes et al., 2009</xref>). Clinical studies are needed to evaluate the safety and efficacy of this antiviral in humans.
</p>
